ELND 006

Overview

ELND 006 (Compound 30) is a metabolically stable γ-secretase inhibitor designed to selectively inhibit amyloid beta (Aβ) generation while sparing Notch signaling. It was developed through a synthetic strategy emphasizing diversity and chirality. ELND 006, along with its analog ELND007 (Compound 34), progressed into human clinical trials. In preclinical studies, both compounds demonstrated effective reduction of Aβ levels in vitro and in vivo. Comparisons with other γ-secretase inhibitors like Semagacestat, Begacestat, and Avagacestat underscored their potency and specificity in lowering Aβ levels in cerebrospinal fluid (CSF) of healthy human volunteers, suggesting potential therapeutic efficacy in Alzheimer's disease.

Application

Products | Products > Disease Areas > Alzheimer's Disease | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Cancer | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Neurodegenerative Disease | Products > Signaling Pathways > Neuronal Signaling | Products > Signaling Pathways > Stem Cell/Wnt | Products > Research Areas > Metabolic Disease | Products > Signaling Pathways > γ-secretase | Products > Signaling Pathways > Amyloid-β

Product Information

• Catalog No.: HY-16632
• CAS No.: 1333990-84-3
• Molecular Formula: C20H14F5N3O2S
• Molecular Weight: 455.40
• Purity: 99.7%
• Storage: -20°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
• Availability: In-stock

Source

Original product source